Please assess the completion status of the following clinical trial:

Trial Title: Precision Treatment With Angiotensin Converting Enzyme Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women over 20 years of age and less than 79 years of age~* Hypertension~* No history of ACEI use~Exclusion Criteria:~* Acute coronary syndrome, cerebrovascular accident, symptomatic peripheral artery disease, or coronary revascularization in the past three months~* Decompensated heart failure~* Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg~* Hemoglobin A1c \>9.0%~* Thyroid dysfunction~* Serum transaminase \>2 times the upper limit of normal levels~* Serum creatinine \>2.0 mg/dL~* Cancer~* Pregnant or breast-feeding women, and women of childbearing potential~* Patients who refused to participate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): This group will perform genetic study for predicting adverse reaction to ACEI. Based on the result of genetic study, participants will receive ACEI or ARB.
- Control (Type: ACTIVE_COMPARATOR): Participants will receive ACEI without genetic study.

Based on this trial design, predict the completion outcome and termination type (if applicable).